Business UpdateMay 14, 2026, 05:11 PM
Profound Medical's TULSA Procedure Highlighted at AUA2026
AI Summary
Profound Medical Corp. announced that its TULSA Procedure™ will be highlighted in four oral presentations at the upcoming American Urological Association's Annual Meeting on May 16, 2026. The company also revealed an initiative to explore integrating PSMA PET molecular imaging technologies with the TULSA Procedure to enhance treatment planning and patient monitoring for prostate ablation. This development aims to empower physicians with greater precision and confidence in delivering tailored treatments.
Key Highlights
- Profound Medical's TULSA Procedure will be featured in four oral presentations at the American Urological Association's Annual Meeting on May 16, 2026.
- The company is launching an initiative to integrate PSMA PET molecular imaging technologies with the TULSA Procedure.
- Presentations will cover multicenter registry data, morphologic and perfusion changes, 12-month safety/efficacy from a phase 2 trial, and real-world data.
- Profound will host TULSA-PRO demonstrations at Booth #413, showcasing its compatibility with Siemens MAGNETOM Free.Max MR.
- The integration aims to enhance ablation planning and monitoring for localized prostate cancer, supporting personalized treatment strategies.
Price Impact
More from PROF